RxDoctor Payments Data

Anna Bortnick

Interventional Cardiology · Bronx, NYNPI 1346391869

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,416 of the $3,953 with a category attached, or 86.4%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.

$3,953in general payments, 2019–2025

Across 40 payments — averaging $98.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$831
  • Medtronic$539
  • Getinge USA Sales, LLC$538
  • Cardiovascular Systems Inc.$392
  • Abiomed$370
  • Abbott$307
  • plus $978 from 9 others
$188,852in research payments, 2019–2025

Across 117 payments — averaging $1614.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$145K
  • Abbott$16K
  • Amgen$12K
  • Janssen Research & Development, LLC$12K
  • AstraZeneca$5K

What the payments were for

  • Travel & lodging$53814%
  • Food & beverage$3,41686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,953 in reported general payments places this provider in the 30th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$54,057
Medicare patients
94
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$36,793
EntrestoSacubitril/Valsartan34$32,112
Repatha SureclickEvolocumab28$22,350
OzempicSemaglutide15$15,850
EliquisApixaban18$15,266
XareltoRivaroxaban12$15,046
BrilintaTicagrelor13$11,314
Metoprolol Succinate101$1,814
Ezetimibe23$945
Nifedipine ErNifedipine35$814
Atorvastatin Calcium77$798
Rosuvastatin Calcium48$553
Losartan Potassium35$342
Nitroglycerin13$334
ClopidogrelClopidogrel Bisulfate32$267

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →